Xencor reported $85.49M in Sales Revenues for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Abbvie ABBV:US $ 13538M 1348M
Alnylam Pharmaceuticals ALNY:US $ 213.26M 45.28M
Amgen AMGN:US $ 6238M 608M
Arrowhead Research ARWR:US $ 151.8M 124.37M
AstraZeneca AZN:LN 11390M 621M
Biogen BIIB:US $ 2531.8M 202M
Bristol Myers Squibb BMY:US $ 11648M 337M
Cytokinetics CYTK:US $ 1.15M 54.45M
Epizyme EPZM:US $ 8.7M 2.89M
GlaxoSmithKline GSK:LN 9780M 253M
Johnson & Johnson JNJ:US $ 23426M 1378M
Karyopharm Therapeutics KPTI:US $ 47.67M 78.6M
Macrogenics MGNX:US $ 11.1M 3.05M
Merk MRK:US $ 15901M 2380M
Novartis NOVN:VX SF 12814M 708M
Pfizer PFE:US $ 25661M 2026M
Regeneron Pharmaceuticals REGN:US $ 2965.1M 1986.6M
Roche Holding ROG:VX 16.44B 474M
Seattle Genetics SGEN:US $ 426.46M 3.39M
Xencor XNCR:US $ 85.5M 68.52M